Local abnormal ventricular activity (LAVA) is composed of high-frequency, mainly low voltage signals that represent near-field signals from slow-conducting tissue and thus potential VT isthmuses. The identification of LAVA potentials and their modification have usually been a complimentary component of the substrate-based modification of scar related ventricular arrhtyhmias. With better identification through technical solutions and improved algorithms, LAVA modification may be feasible for treatment in therapy refractory VT.
As of 2019 we started LAVA modification only in a subset of patients with therapy refractory ventricular tachycardia. The cohort icludes 55% patient with ischemic cardiomyopathy and 45% with dilated cardiomyopathy. 80% are ICD recipients. These patients were now retrospectively analysed in depth. The endpoint is time to relapse of ventricular tachycardia or ICD shock or death due to malignant arrhythmia. We evaluated all patients we treated accordingly from March 2019 through October 2020. No patient was excluded.
Study Type
OBSERVATIONAL
Enrollment
22
In a subset of patients with known therapy refractory arrhythmia sole LAVA modification is fashioned
Krankenhaus Landshut Achdorf
Landshut, Bavaria, Germany
VT
occurrence/documentation of ventricular arrhythmia in participant after substrate modification during follow-up period (either Holter ECG or defibrillator interogation or ILR/ICM or electrophysiology study)
Time frame: 12 months
appropriate therapy delivered by defibrillator (ICD)
appropriate therapy (shock, ATP) delivered by ICD in participants during follow-up period
Time frame: 12 months
death
patient succumbed due to malignant ventricular arrhythmia or therapy
Time frame: 12 months
death any cause
death any cause during observation period
Time frame: 36 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.